1. Home
  2. KRYS vs TNL Comparison

KRYS vs TNL Comparison

Compare KRYS & TNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • TNL
  • Stock Information
  • Founded
  • KRYS 2015
  • TNL 1990
  • Country
  • KRYS United States
  • TNL United States
  • Employees
  • KRYS N/A
  • TNL N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • TNL Hotels/Resorts
  • Sector
  • KRYS Health Care
  • TNL Consumer Discretionary
  • Exchange
  • KRYS Nasdaq
  • TNL Nasdaq
  • Market Cap
  • KRYS 3.6B
  • TNL 2.9B
  • IPO Year
  • KRYS 2017
  • TNL N/A
  • Fundamental
  • Price
  • KRYS $125.96
  • TNL $48.54
  • Analyst Decision
  • KRYS Strong Buy
  • TNL Buy
  • Analyst Count
  • KRYS 8
  • TNL 10
  • Target Price
  • KRYS $211.13
  • TNL $59.20
  • AVG Volume (30 Days)
  • KRYS 436.2K
  • TNL 613.9K
  • Earning Date
  • KRYS 05-06-2025
  • TNL 07-23-2025
  • Dividend Yield
  • KRYS N/A
  • TNL 4.61%
  • EPS Growth
  • KRYS 109.01
  • TNL 10.67
  • EPS
  • KRYS 4.16
  • TNL 5.99
  • Revenue
  • KRYS $333,448,000.00
  • TNL $3,882,000,000.00
  • Revenue This Year
  • KRYS $48.66
  • TNL $4.04
  • Revenue Next Year
  • KRYS $49.81
  • TNL $3.73
  • P/E Ratio
  • KRYS $30.31
  • TNL $8.80
  • Revenue Growth
  • KRYS 247.53
  • TNL 2.51
  • 52 Week Low
  • KRYS $122.80
  • TNL $37.77
  • 52 Week High
  • KRYS $219.34
  • TNL $58.95
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 31.65
  • TNL 53.69
  • Support Level
  • KRYS $123.03
  • TNL $48.07
  • Resistance Level
  • KRYS $127.59
  • TNL $49.09
  • Average True Range (ATR)
  • KRYS 4.59
  • TNL 0.99
  • MACD
  • KRYS 0.39
  • TNL -0.22
  • Stochastic Oscillator
  • KRYS 18.15
  • TNL 36.38

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About TNL Travel Leisure Co. Common Stock

Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.

Share on Social Networks: